Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guangzhou Towe Biotech Co. Ltd. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution is handled by 1 distinct examiner and 1 distinct art unit, which points to a narrow administrative footprint. This concentration implies that the company's immediate patent prospects are tied to the specific standards of 1 art unit within the biotechnology sector. This administrative status suggests that the company is maintaining a lean active portfolio at this time.
The busiest examiner assigned to the portfolio is REYNOLDS, FRED H, who is responsible for 1 pending office action. Since REYNOLDS, FRED H is the only examiner currently reviewing the company's work, their individual perspective will be the deciding factor for this pending matter. For a firm in the Biotechnology & Pharmaceuticals space, this focus requires a precise understanding of the examiner's prior rulings to navigate the current matter effectively. The involvement of only 1 distinct examiner simplifies the management of the company's current intellectual property assets.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270396 | MEDICAL DEVICE, HYDROGEL, PREPARATION METHOD THEREFOR, AND USE THEREOF | REYNOLDS, FRED H | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270396 | MEDICAL DEVICE, HYDROGEL, PREPARATION METHOD THEREFOR, AND USE THEREOF | REYNOLDS, FRED H | 14d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270396 | MEDICAL DEVICE, HYDROGEL, PREPARATION METHOD THEREFOR, AND USE THEREOF | REYNOLDS, FRED H | 1658 | §101§103Other | Non-Final OA | 14d | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangzhou Towe Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fred H Reynolds has the most, with 1 of Guangzhou Towe Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
